September 28, 2018 - 9:00 AM
September 28, 2018 - 2:00 PM
Assessment of Needs
HCV disease management has seen rapid advances, and medical practitioners can now use direct-acting antiviral agents to treat and even cure many people. Consequently, the field needs clinical decision makers, including HIV disease management and infectious disease specialists, who are well versed in the complexities of antiretroviral management or who are involved or interested in HCV medicine to join their hepatology and gastroenterology colleagues in providing care for HCV-infected patients.
After completion of this activity, learners will be able to describe:
- Screening and testing for hepatitis C virus (HCV) infection and staging of the liver for the nonhepatologist
- Strategies for state-of-the-art treatment for HCV infection in:
- Treatment-naive and -experienced patients
- The setting of HCV in HIV/HCV coinfection
- Special patient populations, such as those who have advanced liver disease
- Posttreatment screening for hepatocellular carcinoma
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
The small-group, interactive format is designed for clinical decision makers (physicians, nurse practitioners, and physician assistants) who plan to begin treating patients with HCV infection, who have experience in treating HCV infection, or who would like to update their knowledge of HCV infection management. The workshop is also suitable for PharmDs.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 4.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
This program is approved for 4.5 hours of pharmacotherapy credit.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 4.5 hours (0.45 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-18-271-L01-P
This workshop is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc